{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,18]],"date-time":"2026-08-18T02:17:10Z","timestamp":1787019430329,"version":"build-2736575974"},"reference-count":21,"publisher":"Wiley","issue":"7","license":[{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"},{"start":{"date-parts":[[2019,8,1]],"date-time":"2019-08-01T00:00:00Z","timestamp":1564617600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/journals.sagepub.com\/page\/policies\/text-and-data-mining-license"}],"content-domain":{"domain":["journals.sagepub.com"],"crossmark-restriction":true},"short-container-title":["UEG Journal"],"published-print":{"date-parts":[[2019,8]]},"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>The management of inflammatory bowel disease in patients who have previously undergone liver transplantation can be a clinical challenge. There are serious concerns among physicians regarding the use of biologics for treating such immuno\u2010compromised patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>We performed a systematic review on vedolizumab therapy in transplant recipients to assess its safety.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>PubMed\/Embase\/Scopus were searched up to November 2018 to identify papers regarding liver transplant recipients and therapy with vedolizumab. Primary outcomes were adverse events. Secondary outcomes were liver transplant and inflammatory bowel disease outcomes.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>Eight studies (31 patients) were included. Nine out of 31 patients experienced an infection within a mean follow\u2010up time ranging from 5\u201320 months. No malignancies were reported. Inflammatory bowel disease clinical response was experienced by 20\/26 patients. Abnormalities in liver tests were recorded in 2\/22 patients.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>Vedolizumab may be considered safe for treating inflammatory bowel disease in liver transplant recipients. Caution is recommended for patients with an unstable liver graft function.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1177\/2050640619858050","type":"journal-article","created":{"date-parts":[[2019,6,21]],"date-time":"2019-06-21T01:12:18Z","timestamp":1561079538000},"page":"875-880","update-policy":"https:\/\/doi.org\/10.1177\/sage-journals-update-policy","source":"Crossref","is-referenced-by-count":21,"title":["Safety of vedolizumab in liver transplant recipients: A systematic review"],"prefix":"10.1002","volume":"7","author":[{"given":"Marco","family":"Spadaccini","sequence":"first","affiliation":[{"name":"Department of Biomedical Sciences<!--<institution-id institution-id-type=\"Ringgold\">437807<\/institution-id>--> Humanitas University Rozzano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessio","family":"Aghemo","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences<!--<institution-id institution-id-type=\"Ringgold\">437807<\/institution-id>--> Humanitas University Rozzano Italy"},{"name":"Internal Medicine and Hepatology Humanitas Clinical and Research Center Rozzano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Flavio","family":"Caprioli","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ana","family":"Lleo","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences<!--<institution-id institution-id-type=\"Ringgold\">437807<\/institution-id>--> Humanitas University Rozzano Italy"},{"name":"Internal Medicine and Hepatology Humanitas Clinical and Research Center Rozzano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Federica","family":"Invernizzi","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico Milan Italy"},{"name":"Division of Gastroenterology and Hepatology A. M. and A. Migliavacca Center for Liver Disease Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Silvio","family":"Danese","sequence":"additional","affiliation":[{"name":"Department of Biomedical Sciences<!--<institution-id institution-id-type=\"Ringgold\">437807<\/institution-id>--> Humanitas University Rozzano Italy"},{"name":"Department of Gastroenterology Humanitas Clinical and Research Center Rozzano Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maria F","family":"Donato","sequence":"additional","affiliation":[{"name":"Fondazione IRCCS Ca'Granda Ospedale Maggiore Policlinico Milan Italy"},{"name":"Division of Gastroenterology and Hepatology A. M. and A. Migliavacca Center for Liver Disease Milan Italy"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2019,8]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMra064928"},{"key":"e_1_2_7_3_2","doi-asserted-by":"publisher","DOI":"10.1002\/hep.23294"},{"key":"e_1_2_7_4_2","doi-asserted-by":"publisher","DOI":"10.1038\/ajg.2013.163"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.2147\/DHPS.S28801"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1093\/ecco-jcc\/jjx057"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1215734"},{"key":"e_1_2_7_8_2","doi-asserted-by":"publisher","DOI":"10.1136\/gutjnl-2015-311079"},{"key":"e_1_2_7_9_2","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.g7647"},{"key":"e_1_2_7_10_2","unstructured":"WellsGA SheaB O'ConnellD et al.The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomized studies in meta-analysis http:\/\/www.ohri.ca\/programs\/clinical_epidemiology\/oxford.asp. (2011 accessed 25 November 2012)."},{"key":"e_1_2_7_11_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.13861"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1097\/MIB.0000000000000906"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1136\/flgastro-2016-100711"},{"key":"e_1_2_7_14_2","doi-asserted-by":"crossref","first-page":"659","DOI":"10.17235\/reed.2017.5024\/2017","article-title":"Efficacy and safety of vedolizumab as a treatment option for moderate to severe refractory ulcerative colitis in two patients after liver transplant due to primary sclerosing cholangitis","volume":"109","author":"Olmedo Martin RV","year":"2017","journal-title":"Rev Esp Enferm Dig"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.24757"},{"key":"e_1_2_7_16_2","doi-asserted-by":"crossref","first-page":"S845","DOI":"10.1016\/S0016-5085(18)32865-8","article-title":"Real world outcomes of vedolizumab for inflammatory bowel disease post liver transplantation","volume":"154","author":"Peverelle M","year":"2018","journal-title":"Gastroenterology"},{"key":"e_1_2_7_17_2","doi-asserted-by":"crossref","first-page":"S358","DOI":"10.1093\/ecco-jcc\/jjx180.628","article-title":"Vedolizumab for UC after infliximab failure in PSC patients after OLTx: Two case reports","volume":"12","author":"Drastich P","year":"2018","journal-title":"J Crohns Colitis"},{"key":"e_1_2_7_18_2","doi-asserted-by":"crossref","first-page":"S147","DOI":"10.1093\/ecco-jcc\/jjx002.266","article-title":"Use of vedolizumab in a transplanted liver patient: A case report of the first experience in a liver transplant referral center in Argentina","volume":"11","author":"Daffra PR","year":"2017","journal-title":"J Crohns Colitis"},{"key":"e_1_2_7_19_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14525"},{"key":"e_1_2_7_20_2","doi-asserted-by":"publisher","DOI":"10.1111\/apt.14829"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1002\/lt.24350"},{"key":"e_1_2_7_22_2","article-title":"Characteristics and outcomes of liver transplantation for primary biliary cholangitis (PBC) in young patients: Analysis of the United Network for Organ Sharing Database","author":"Singh A","journal-title":"Transplantation"}],"container-title":["United European Gastroenterology Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/2050640619858050","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/full-xml\/10.1177\/2050640619858050","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1177\/2050640619858050","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,3]],"date-time":"2023-09-03T07:18:14Z","timestamp":1693725494000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1177\/2050640619858050"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,8]]},"references-count":21,"journal-issue":{"issue":"7","published-print":{"date-parts":[[2019,8]]}},"alternative-id":["10.1177\/2050640619858050"],"URL":"https:\/\/doi.org\/10.1177\/2050640619858050","archive":["Portico"],"relation":{},"ISSN":["2050-6406","2050-6414"],"issn-type":[{"value":"2050-6406","type":"print"},{"value":"2050-6414","type":"electronic"}],"subject":[],"published":{"date-parts":[[2019,8]]}}}